PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today provided highlights from the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference held in Denver, Colorado. In addition to its participation in the event, Eyevensys also held a successful meeting with principal investigators involved in its clinical trials evaluating EYS606, a plasmid DNA encoding an anti-TNF? protein for non-infectious uveitis (NIU).
Eyevensys has formed separate multi-year strategic partnerships with Phillips-Medisize and Minnetronix Medical to develop the next version of its Electrotransfection System. These efforts have already begun, with Phillips-Medisize working on optimizing the design of the system’s ocular device component, which injects the DNA plasmid solution into the eye, while Minnetronix upgrades the electrical pulse generator powering the system.
Eyevensys, a private, clinical-stage biotechnology company that develops non-viral gene therapies for eye disease, today announces that it has raised $ 12 million in a Round B Plus Series led by Korea Investment Partners;Â existing investors will also participate in the round table.
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announces it has raised $12M in a Series B Plus funding round. Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round.
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announced the U.S. Food and Drug Administration (FDA) has granted an orphan-drug designation (ODD) for EYS611 for the treatment of retinitis pigmentosa (RP).